bioMérieux SA

Today, a brief rundown of news from Novo Nordisk and Terns Pharmaceuticals, as well as updates from Corcept Therapeutics and BioMrieux that you may have missed.Early numbers from Novo Nordisks launch of an oral form of Wegovy continued to outpace expectations. According to analytics shared with Wall Street analysts, about 18,000 prescriptions were written for the week ending Jan. 16, a very strong figure following the roughly 3,000 issued the prior week, wrote Evercore ISIs Umer Raffat. As with the previous total, the number didnt include prescriptions through Novos online service and, notably at least so far, hasnt come at the expense of the injectable Wegovy, Raffat noted. Novo shares ticked up another 2% and have climbed about 20% over the last month. Ben FidlerTerns Pharmaceuticals has amended the licensing deal surrounding its closely watched leukemia drug. According to a regulatory filing made public Thursday, Terns acquired from Chinas Hansoh Pharmaceutical the ability to license the drug, known as TERN-701 and in testing for chronic myeloid leukemia, in territories where Hansoh doesn't have rights. Under the terms of a 2020 deal, Hansoh had to clear other partnering decisions. But for a $1 million upfront payment and a small royalty, Terns can now seek other collaborations “without consent“ from Hansoh, noted Mizuho Securities' Graig Suvannavejh. The move should “clear the way for a potential partnership,“ he added. TERN-701 is seen by some analysts as potentially disrupting the treatment landscape for CML. Ben FidlerCorcept Therapeutics said Thursday that an experimental treatment its developing helped extend survivalin a pivotal trial in ovarian cancer. A regimen involving the drug, relacorilant, and a kind of chemotherapy was associated with a 35% reduction in the risk of death compared to treatment with that chemotherapy alone.Corcept had previously revealed that the treatment met its other main goal in the study by meaningfully improving progression-free survival.The Food and Drug Administration in December rejected an application to approve relacorilant for a kind of hypertension. Its set to make a decision on the drugs use in ovarian cancer by July 11. Corcept shares climbed by double digits Thursday. Delilah AlvaradoFrench firm BioMrieux has acquired all of the rights it didn't own in Accellix, a company that provides quality control assistance and helps speed up the manufacturing of cell therapies. BioMrieux has been collaborating with Accellix since 2020 and, prior to the acquisition, owned 10% of its stock. On Thursday, it agreed to pay 35 million euros, or about $41 million, to buy the rest of the company. The deal puts BioMrieux “at the forefront of innovation and quality control for advanced therapies,“ which include cell and gene therapies, the company said in a statement. Ben Fidler '

DEVENS, Mass., Jan. 12, 2026 /PRNewswire/ -- Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced that Stephane Bancel, the Chief Executive Officer of Moderna Inc. who led that company's successful development, production, scaling, and global adoption of the COVID-19 vaccine, has joined as an Independent Member of the Board of Directors. Bancel has served as Moderna's CEO and as a member of the company's board since 2011. He is best known for leading Moderna's effort in early 2020 to focus on the successful development of one of the first COVID-19 vaccines in record time under Operation Warp Speed. He is also a partner in Flagship Pioneering, the life science-focused venture capital firm that helped to launch Moderna. Previously, Bancel spent five years as the CEO of bioMerieux SA, a French diagnostics company, and he also served in leadership roles at Eli Lilly & Co. "Stephane's expertise in developing an organizational culture that can push through leading-edge innovations, at scale, on urgent timelines will be valuable to CFS as we continue to lead this global energy transition to fusion," said Bob Mumgaard, Chief Executive Officer and Co-founder of CFS. "We are excited to have Stephane on our team as we move to commercialize this transformational energy technology." Bancel was also an early investor in CFS, recognizing that the team had the discipline to execute the research, development, and engineering required to fulfill the scientific objectives. "I am pleased to have the opportunity to work with the CFS team to unlock fusion's promise of abundant energy at a time of unprecedented demand for power worldwide," Bancel said. "The CFS team has the passion for the science, as well as the engineering and execution – all of the pieces needed to scale. The company is at the forefront of an emerging industry that will introduce a new era of energy independence and security, and I look forward to being a part of it." Bancel is the second new member to join CFS' board this year. In August, CFS announced that Chris Liddell, a former White House official who has also served as CFO at Microsoft Corp. and General Motors Co., joined as an Independent Board Member. About Commonwealth Fusion Systems Commonwealth Fusion Systems is the world's largest and leading private fusion company. The company's marquee fusion project, SPARC, will generate net energy, paving the way for limitless carbon-free energy. The company has raised almost $3 billion in capital since it was founded in 2018. SPARC® and ARC™ are trademarks of Commonwealth Fusion Systems®. Media contacts: Commonwealth Fusion Systems [email protected] SOURCE Commonwealth Fusion Systems 21% more press release views with Request a Demo

Oxford Nanopore has reached a major regulatory milestone with the registration of its first In Vitro Diagnostic (“IVD”) device in the UK and Europe: the GridION™ Dx. OXFORD, England--(BUSINESS WIRE)-- #Nanopore --Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company’s first IVD device registered in the UK and Europe. The CE and UKCA certification confirms that GridION™ Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to sequencing-based diagnostics. “Being CE and UKCA marked for GridION™ Dx is an important step as we build the foundations for clinical use in regulated markets,” said Gordon Sanghera, CEO Oxford Nanopore Technologies . “This milestone demonstrates regulatory readiness and supports the deployment of GridION™ Dx as a diagnostic product for use in clinical environments within the UK and Europe.” GridION Dx will initially be available through specified partnerships, with the first application being infectious disease characterisation. The Oxford Nanopore platform delivers information-rich insights and rapid time to results, in a way that is accessible and affordable – critical factors for shaping future clinical workflows and enabling expansion into areas such as oncology and genetic conditions. The first product, available in partnership with bioMérieux, will integrate with AmPORE-TB, a multidrug-resistant tuberculosis assay, and underscores this strategic approach. bioMérieux is a world leader in the field of in vitro diagnostics recognised for its extensive portfolio of CE-marked solutions spanning microbiology, immunoassays, and molecular biology. AmPORE-TB has been introduced as a research use only (“RUO”) application and, already in clinical trials, is on a defined pathway towards a fully regulated IVD assay on GridION Dx. This underlines both companies’ commitment to bringing sequencing-based tuberculosis testing to clinical settings over time. Dr Charles K. Cooper, Executive Vice President, Chief Medical Officer, bioMérieux stated: "The regulatory approval of GridION™ Dx represents a major milestone in expanding access to innovative sequencing-based solutions like AmPORE-TB. This achievement brings us closer to equipping healthcare professionals with advanced tools to combat antimicrobial resistance, enabling faster, more informed decisions and improving patient outcomes worldwide." About Oxford Nanopore Technologies Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: Contacts Contact Oxford Nanopore Technologies Media@nanoporetech.com